Last reviewed 2026-05-31 · How we verify

DS003 vaginal tablet

International Partnership for Microbicides, Inc. · Phase 1 active Small molecule ✓ Verified May 2026 Quality 0/100

DS003 vaginal tablet is a Small molecule drug developed by International Partnership for Microbicides, Inc.. It is currently in Phase 1 development.

DS003 vaginal tablet is a small molecule intervention being studied for its safety and pharmacokinetics in healthy HIV-negative women. It is being evaluated in a clinical trial for its potential use in HIV prevention.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DS003 vaginal tablet
Sponsor	International Partnership for Microbicides, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DS003 vaginal tablet CI brief — competitive landscape report
DS003 vaginal tablet updates RSS · CI watch RSS
International Partnership for Microbicides, Inc. portfolio CI

Frequently asked questions about DS003 vaginal tablet

What is DS003 vaginal tablet?

DS003 vaginal tablet is a Small molecule drug developed by International Partnership for Microbicides, Inc..

Who makes DS003 vaginal tablet?

DS003 vaginal tablet is developed by International Partnership for Microbicides, Inc. (see full International Partnership for Microbicides, Inc. pipeline at /company/international-partnership-for-microbicides-inc).

What development phase is DS003 vaginal tablet in?

DS003 vaginal tablet is in Phase 1.

Manufacturer: International Partnership for Microbicides, Inc. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing